Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyAzapropazone
Identification
- Name
- Azapropazone
- Accession Number
- DB07402
- Type
- Small Molecule
- Groups
- Withdrawn
- Description
- Not Available
- Structure
Structure for Azapropazone (DB07402)
- Synonyms
- azapropazona
- Azapropazone
- International/Other Brands
- Rheumox (Amdipharm Mercury Company Limited)
- Categories
- Agents causing hyperkalemia
- Analgesics
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Antigout Preparations
- Antiinflammatory and Antirheumatic Products
- Antiinflammatory and Antirheumatic Products, Non-Steroids
- Central Nervous System Agents
- Musculo-Skeletal System
- Nephrotoxic agents
- Peripheral Nervous System Agents
- Renal Agents
- Sensory System Agents
- Triazines
- Uricosuric Agents
- UNII
- K2VOT966ZI
- CAS number
- 13539-59-8
- Weight
- Average: 298.3397
Monoisotopic: 298.14297584 - Chemical Formula
- C16H18N4O2
- InChI Key
- WOIIIUDZSOLAIW-NSHDSACASA-N
- InChI
- InChI=1S/C16H18N4O2/c1-5-6-11-14(21)19-13-9-10(2)7-8-12(13)17-16(18(3)4)20(19)15(11)22/h5,7-9,11H,1,6H2,2-4H3/t11-/m0/s1
- IUPAC Name
- (4S)-7-(dimethylamino)-12-methyl-4-(prop-2-en-1-yl)-2,6,8-triazatricyclo[7.4.0.0²,⁶]trideca-1(13),7,9,11-tetraene-3,5-dione
- SMILES
- [H][C@@]1(CC=C)C(=O)N2N(C1=O)C1=CC(C)=CC=C1N=C2N(C)C
Pharmacology
- Indication
- Not Available
- Pharmacodynamics
- Not Available
- Mechanism of action
- Not Available
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half life
- Not Available
- Clearance
- Not Available
- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction (R)-warfarin The risk or severity of bleeding and hemorrhage can be increased when Azapropazone is combined with (R)-warfarin. (S)-Warfarin The risk or severity of bleeding and hemorrhage can be increased when Azapropazone is combined with (S)-Warfarin. 1-(3-Mercapto-2-Methyl-Propionyl)-Pyrrolidine-2-Carboxylic Acid The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Azapropazone is combined with 1-(3-Mercapto-2-Methyl-Propionyl)-Pyrrolidine-2-Carboxylic Acid. 4-hydroxycoumarin The risk or severity of bleeding and hemorrhage can be increased when Azapropazone is combined with 4-hydroxycoumarin. Abacavir Azapropazone may decrease the excretion rate of Abacavir which could result in a higher serum level. Abciximab The risk or severity of bleeding and hemorrhage can be increased when Azapropazone is combined with Abciximab. Acarbose Azapropazone may decrease the excretion rate of Acarbose which could result in a higher serum level. Acebutolol Azapropazone may decrease the antihypertensive activities of Acebutolol. Aceclofenac The risk or severity of adverse effects can be increased when Aceclofenac is combined with Azapropazone. Acemetacin The risk or severity of adverse effects can be increased when Azapropazone is combined with Acemetacin. - Food Interactions
- Not Available
References
- Synthesis Reference
Molnar, I., Wagner-Jauregg,T., Jahn, U. and Mixich, G.; US. Patent 3,349,088; October 24, 1967; assigned to Siegfried AG, Switzerland Molnar, I.,Wagner-Jauregg,T., Jahn, U. and Mixich, G.; US. Patent 3,482,024; December 2, 1969; assigned to Siegfried AG.
- General References
- Not Available
- External Links
- ATC Codes
- M01AX04 — Azapropazone
- PDB Entries
- 2bx8 / 2bxi / 2bxk
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 187 Molnar, I., Wagner-Jauregg,T., Jahn, U. and Mixich, G.; US. Patent 3,349,088; October 24, 1967; assigned to Siegfried AG, Switzerland Molnar, I.,Wagner-Jauregg,T., Jahn, U. and Mixich, G.; US. Patent 3,482,024; December 2, 1969; assigned to Siegfried AG. - Predicted Properties
Property Value Source Water Solubility 0.641 mg/mL ALOGPS logP 0.92 ALOGPS logP 2.08 ChemAxon logS -2.7 ALOGPS pKa (Strongest Acidic) 0.52 ChemAxon pKa (Strongest Basic) 7.58 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 4 ChemAxon Hydrogen Donor Count 0 ChemAxon Polar Surface Area 56.22 Å2 ChemAxon Rotatable Bond Count 2 ChemAxon Refractivity 85.69 m3·mol-1 ChemAxon Polarizability 31.94 Å3 ChemAxon Number of Rings 3 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 1.0 Blood Brain Barrier + 0.9389 Caco-2 permeable + 0.5728 P-glycoprotein substrate Non-substrate 0.5961 P-glycoprotein inhibitor I Inhibitor 0.8281 P-glycoprotein inhibitor II Inhibitor 0.6484 Renal organic cation transporter Non-inhibitor 0.7843 CYP450 2C9 substrate Non-substrate 0.8218 CYP450 2D6 substrate Non-substrate 0.8107 CYP450 3A4 substrate Substrate 0.6289 CYP450 1A2 substrate Inhibitor 0.5528 CYP450 2C9 inhibitor Non-inhibitor 0.8735 CYP450 2D6 inhibitor Non-inhibitor 0.9188 CYP450 2C19 inhibitor Non-inhibitor 0.8614 CYP450 3A4 inhibitor Non-inhibitor 0.8273 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.725 Ames test AMES toxic 0.5466 Carcinogenicity Non-carcinogens 0.8321 Biodegradation Not ready biodegradable 1.0 Rat acute toxicity 2.4784 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.7311 hERG inhibition (predictor II) Non-inhibitor 0.8171
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as aminotriazines. These are organic compounds containing an amino group attached to a triazine ring.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Triazines
- Sub Class
- Aminotriazines
- Direct Parent
- Aminotriazines
- Alternative Parents
- Pyrazolidinones / Benzenoids / 1,3-dicarbonyl compounds / 1,2,4-triazines / Guanidines / Carboxylic acid hydrazides / Propargyl-type 1,3-dipolar organic compounds / Azacyclic compounds / Organopnictogen compounds / Organic oxides show 1 more
- Substituents
- Amino-1,2,4-triazine / Aminotriazine / Pyrazolidinone / 1,3-dicarbonyl compound / Benzenoid / 1,2,4-triazine / Pyrazolidine / Carboxylic acid hydrazide / Guanidine / Azacycle show 12 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- Not Available
Carriers
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- General Function
- Toxic substance binding
- Specific Function
- Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
- Gene Name
- ALB
- Uniprot ID
- P02768
- Uniprot Name
- Serum albumin
- Molecular Weight
- 69365.94 Da
References
- Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Drug created on September 15, 2010 15:21 / Updated on November 02, 2018 06:32